POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial hopes to tame rare blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called PRT12396 in about 100 people with polycythemia vera or myelofibrosis, which are types of blood cancers. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific gene m…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:44 UTC
-
New hope for myelofibrosis patients who fail current therapies
Disease control Recruiting nowThis early-stage study tests an experimental pill, AJ1-11095, in people with a bone marrow cancer called myelofibrosis. Participants must have already tried a standard JAK2 inhibitor without success. The main goals are to check the drug's safety and find the best dose for future …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Blood cancer drug bomedemstat tested for Long-Term safety in 400 patients
Disease control Recruiting nowThis study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who have already been taking the drug bomedemstat and are doing well on it. The goal is to collect more information on the drug's long-term safety and how well it continues to wo…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New hope for myelofibrosis: tasquinimod trial launches
Disease control Recruiting nowThis study tests a drug called tasquinimod, given alone or with another drug (ruxolitinib), to see if it can help control myelofibrosis—a serious bone marrow disorder. About 33 adults with primary myelofibrosis or related forms who haven't responded to other treatments will take …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New study aims to map Real-World care for rare bone marrow disease
Knowledge-focused Recruiting nowThis study is a registry that will follow about 200 people in Germany who have myelofibrosis (a rare bone marrow disorder) and anemia. It does not test a new treatment but instead collects information on which therapies patients receive, how their blood counts and spleen size res…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 17, 2026 02:39 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC